Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Vella Bonanno, Patricia, Ermisch, Michael, Godman, Brian, Martin, Antony P., Van Den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Eriksson, Irene, Fürst, Jurij, Gad, Mohamed, Greičiūtė-Kuprijanov, Ieva, van der Graaff, Martin, Gulbinovic, Jolanta, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Langner, Irene, Mardare, Ileana, Markovic-Pekovic, Vanda, Magnusson, Einar, Melien, Oyvind, Meshkov, Dmitry O., Petrova, Guenka I., Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Schuurman, Ad, Ramos, Ricardo, Rodrigues, Jorge, Zara, Corinne, Zebedin-Brandl, Eva, Haycox, Alan
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://ncbi.nlm.nih.gov/pubmed/28878667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00497
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados